<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

qz
AbbVie beat earnings expectations and raised its outlook as newer drugs offset Humira's decline

Skyrizi and Rinvoq together generated more than $6.6 billion in quarterly sales, far outpacing Humira's $688 million [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Beat Saber support is ending on PS VR and PS VR2

It's the end of the line for Beat Saber on PS VR and PS VR2. While you'll still be able to buy and play the base game on both platforms, as well as any songs and music packs that were releas [...]

Match Score: 63.24

Destination
Engadget Podcast: iPhone 16e review and Amazon's AI-powered Alexa+

The keyword for the iPhone 16e seems to be "compromise." In this episode, Devindra chats with Cherlynn about her iPhone 16e review and try to figure out who this phone is actually for. Also, [...]

Match Score: 49.76

venturebeat
Microsoft announces Copilot Cowork with help from Anthropic — a cloud-powered AI agent that works across M365 apps

If you thought Anthropic was about to run away with the enterprise AI business...you're not totally off the mark, actually.This morning, Microsoft announced "Copilot Cowork" a new cloud [...]

Match Score: 49.24

qz
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?

ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch. [...]

Match Score: 49.08

blogspot
How I Get Free Traffic from ChatGPT in 2025 (AIO vs SEO)

Three weeks ago, I tested something that completely changed how I think about organic traffic. I opened ChatGPT and asked a simple question: "What's the best course on building SaaS with Wor [...]

Match Score: 48.53

qz
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?

ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22%, with newer drugs helping offset declines in legacy treat [...]

Match Score: 43.64

qz
AbbVie is buying an eczema and asthma drug developer for nearly $11 billion

The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis [...]

Match Score: 42.68

qz
AbbVie beat profit estimates but cut its forecast — and the stock sank

The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share [...]

Match Score: 41.15

Destination
Engadget's favorite games of 2025

From indies like Silksong, to AAAs like Ghost of Yotei, and everything in between, 2025 truly had it all, and is likely to go down in the history books as one of the best years in gaming. But these ar [...]

Match Score: 41.02